Pfizer makes the competition sneeze - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pfizer makes the competition sneeze

Aug 31, 2000

The proposed merger of Parke Davis with Pfizer would further tighten the latter’s hold in the OTC segment. With Warner Lambert also coming into the Pfizer fold internationally, Pfizer would further inherit brands such as Benadryl, Gelusil and Listerine in its fold. These brands form part of Parke Davis (as Warner Lambert is known in India). Despite apprehensions about the intentions of the management, after the setting up of a 100% subsidiary, Pfizer continues to report healthy growth rates.

The company has delivered a 74% increase in pre–tax profits in the first six months of the current year, despite Becousules (its B–complex vitamin) being brought under price control. Becousules contributes around 20% to the company’s turnover and the National Pharmaceutical Pricing Authority has reduced its prices by 30% in the current year.

Interestingly, Corex and Benadryl dominate the cough segment and merger would only consolidate Pfizer’s dominance in this segment. Infact, Corex has even upstaged Becousules as the top selling brand (as per ORG MARG quoted in the Financial Express) in July 2000.

Brand/Company Value (Rs m) Mkt Share Growth
Overall Mkt 4,844 100% 0.90%
Corex (Pfizer) 694 14.3% 14.1%
Phensedyl (RP) 379 7.8% 21.0%
Beandryl (P.Davis) 246 5.1% -20.4%
Source: Glemark Pharma

Further, Pfizer’s dependence on its six brands would also reduce post meger. (In India six brands viz. Becousules, Lorex, Protinex, Dolonex, Terramycin and Minipress XL account for 80% of the company’s sales.)

Besides, Pfizer has entered into a co–marketing tie up with Shanta Biotech to market the latter’s Hepatitis B vaccine under the brand name Hepashield. Shanta Biotech markets the vaccine under the brand name ‘Shanvac’.

The key impact of the co–marketing deal is the fact that competition within Hep B segment will become considerably tighter. Smithkline Pharma has by far been the leader in this segment with its brand Engerix B dominating the segment, but with Pfizer’s brand name attached to Hepashield, doctors would now be more comfortable recommending Hepashield.

Further the company has plans to introduce an anti–cancer vaccine in India, which if introduced through the listed company could propel’s Pfizer’s bottomline by over 30% next year. (Pfizer’s year ends in November.)

We expect the company to report a net profit in the range of Rs 400 m for the current year (without considering Parke Davis’ numbers) which implies a per share earnings in the range of Rs 17.50. The stock currently quotes at an earning multiple of 33 times. Going forward, this multiple is expected to be sustained despite the presence of 100% subsidiaries of both Pfizer and Parke Davis.


Equitymaster requests your view! Post a comment on "Pfizer makes the competition sneeze". Click here!

  

More Views on News

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 23, 2020 02:59 PM

TRACK PFIZER

PFIZER - ORCHID PHARMA LTD COMPARISON

COMPARE PFIZER WITH

MARKET STATS